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Purpose: Type 2 diabetes (T2D) is highly prevalent worldwide and cataracts are of high incidence in T2D patients. In
this study, we identify genetic variants that predispose type 2 diabetes (T2D) patients to cataracts in the Han-Chinese
residing in Taiwan.
Methods: We conducted a genome-wide association study with a total of 1,715 cases and 2,000 random controls. In the
haplotype study, we defined haplotype 1 (Ht 1) to haplotype 4 (Ht 4) as the alternative alleles of the DM and cataract
related chromosome 3p14.1- 3p14.2 polymorphisms.
Results: The most significant association was detected with rs11129182, rs17047573, and rs17047586 in chromosome
3p14.1- 3p14.2 (p value=3.52×10−7, 8.35×10−8, and 7.65×10−8, respectively). In genotype analysis, the “CT” genotype of
rs11129182, the ‘GG’ genotype of rs17047573, and the ‘GG’ genotype of rs17047586 were significantly different in the
T2D and cataract groups (OR=3.03, 7.47, and 7.51, individually; 95% confidence index (CI): 1.97–4.65, 3.36–16.6, and
3.38–16.7, individually). In the haplotype study, the distribution of the Ht3 and Ht4 between the DM and cataract group
and the control group differed significantly between the two groups (p=0.0004). The odds ratio (OR) of Ht4 was 1.89 and
the 95% confidence interval (CI) was 1.36–2.65.
Conclusions: The major functions of the genes are voltage-dependent anion-selective channel proteins, long myosin light
chain  kinase,  adenylyl  cyclase-associated  proteins  and  retinoic  acid  receptors  and  are  all  closely  related  with  the
pathogenesis of T2D and cataractogenesis. This has helped us understand the pathogenesis of T2D patients with cataracts.
Diabetes mellitus (DM) is one of the major causes of sight
loss. Cataracts, considered a complication of DM, are a cause
of visual impairment that can affect individuals at all ages
[1,2]. Among the various complications of diabetes mellitus
in  the  eyes,  cataracts  are  only  less  critical  then  diabetic
retinopathy  as  cause  of  blindness.  Although  chronic
hyperglycemia and the duration of DM are considered to be
the major risk factors for this diabetic complication [3,4], there
are some patients with severe cataracts while others present
with few risk factors.
A cataract is a clouding that develops in the crystalline
lens of the eye or in its envelope; varying in degree from slight
to complete opacity and obstructing the passage of light. Age-
related cataracts are responsible for 48% of world blindness,
which represents about 18 million people, according to the
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World Health Organization (WHO) [5]. In many countries,
surgical  services  are  inadequate  and  cataracts  remain  the
leading  cause  of  blindness.  Cataracts  are  a  clinically  and
genetically heterogeneous group of eye disorders that causes
visual impairment. At least 34 loci and mutations in 22 genes
have  been  reported  to  be  linked  with  different  forms  of
cataracts. Type 2 diabetes (T2D) affects at least 6% of the
world’s population, and the prevalence is expected to double
worldwide by the year 2025 [6]. T2D is a complex disease
characterized by hyperglycemia that results from impaired
pancreatic β-cell function, decreased insulin action at target
tissues, and increased glucose output by the liver [7]. Both
genetic components and environmental factors contribute to
the pathogenesis of T2D. This disease is considered to be a
polygenic disorder that each genetic variance confers a partial
and additive effect. Only 5%–10% of T2D are monogenic
diabetes with single gene defects. A large amount of effort has
been  devoted  to  finding  common  T2D  genes,  including
genome-wide  linkage,  candidate-gene  and  genome-wide
association studies [8-10]. However, these genes cannot be
held solely responsible for the development of T2D includes
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1206the wide variability of the prevalence of T2D in different
ethnic groups. Cataracts are more common in people with
diabetes than in the general population under the age of 40
years and they are morphologically similar to senile cataracts.
The exact correlation between cataracts and T2D is without a
definite conclusion. Cataracts are a significant complication
of T2D [8-10]. In this study, we aimed to uncover diabetes
susceptibility loci that increase the risk for T2D, as well as
cataracts, in the Chinese population residing in Taiwan.
METHODS
The levels of lens opacity were classified according to the
Lens Opacities Classification System (LOCS) [11,12] in this
study. LOCS involves comparing the slit lamp view of the lens
to a color plate of LOCS III standards (Table 1). LOCS uses
standard reference photographs taken during the slit lamp
examination. LOCS defines the extent of changes in opacity
in  the  cortical  (C)  and  posterior  subcapsular  (P)  regions,
shown in Table 2. It also notes the extent of color changes of
the nucleus, as well as the intensity of nuclear opalescence. In
this study, scores were given to the extent of each lens’ opacity
according to their LOCS classification; for example, N0 was
scored as 0 and NIV was given a 4. After summing up the
scores of the four parts (nuclear color, nuclear opacity, cortical
cataract,  and  posterior  subcapsule),  the  total  score  was
obtained ranging from 0 to 15. The patients in the study group
were patients with cataract score of 10 or more. The patients
in the control group were subjects with cataract score equal to
or less than 3. The patients the in control group, T2D patients
with  cataract  scores  equal  or  less  then  score  3  in  LOCS
cataract evaluation system, were those with corrected visual
acuity (BCVA) of 0.18 logMAR (6/9) or better. The patients
in study group, T2D patients with a cataract score of 10 or
more in LOCS cataract evaluation system, had BCVA of 0.48
logMAR (6/18) or worse.
Subject  participants:  All  T2D  cases  were  diagnosed
using the American Diabetic Association Criteria. Subjects
with  type  1  diabetes,  gestational  diabetes,  and  MODY
(Maturity-onset diabetes of the young) were excluded from
this study. In the first step to study T2D related genes, 2,000
Chinese subjects were randomly selected from the Taiwan
Han-Chinese Cell and Genome Bank as controls [13]. The
random controls and all participating T2D cases were of Han
Chinese origin as the Han Chinese account for 98% of the
Taiwan population. Our study was reviewed by the ethics
committee of CMUH, and informed consent was obtained
from all patients. A comprehensive ophthalmic examination
and  blood  collection  were  performed.  The  study  was
performed  according  to  the  tenets  of  the  Declaration  of
Helsinki for research involving human subjects. In addition,
we investigated HbA1c, total cholesterol, triglyceride, HDL-
cholesterol, LDL-cholesterol, blood urea nitrogen (BUN), and
TABLE 1. LENS OPACITIES CLASSIFICATION (LOC) SYSTEM DEFINES THE EXTENT OF OPACIFICATION OF LENS.
Parameter Features Grade
Nuclear color (NC) The color of the posterior cortical/posterior subcapsular reflex is:  
  <NI standard NC0
  Similar to the NI standard NC1
  >NI standard NC2
Nuclear opalescence (N) The average opalescence of the nucleus is:  
  <=that in N0 N0
  >N0 but <=NI NI
  >NI but <=NII NII
  >NII but <=NIII NIII
  >NIII NIV
Cortical cataract (C) The aggregate extent of linearly organized or clustered opacities is:  
  <=that in C0 C0
  >C0 but <=Ctr (trace) Ctr
  >Ctr but <=CI CI
  >Ctr but <=CII CII
  >Ctr but <=CIII CIII
  >Ctr but <=CIV CIV
  >CIV CV
Posterior subcapsular (P) The aggregate extent of the axial opacity seen in retro-illumination is:
<=that in P0 P0
>P0 but <=PI PI
>PI but <=PII PII
>PII but <=PIII PIII
>PIII PIV
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1207creatinine. Each patient underwent best-corrected distance
visual acuity measurement using a Snellen chart. Visual acuity
was defined as the average value of the corrected visual acuity
of both eyes before examination. An ophthalmic examination
was performed with slit lamp biomicroscopy and indirect
ophthalmoscope  fundus  examination  after  the  pupil  was
maximally dilated with 1.0% tropicamide (Mydriacyl).
Genotyping:  Genomic  DNA  was  extracted  from
peripheral  blood  using  PUREGENE  DNA  isolation  kit
(Gentra Systems, Minneapolis, MN). In the first stage, whole
genome  genotyping  using  Illumina  HumanHap550-Duo
BeadChip  was  performed  by  deCODE  genetics,  Inc.,
Reykjavík,  Iceland.  Genotype  calling  was  done  using  the
standard procedure implemented in Beadstudio, with default
parameters  suggested  by  the  platform  manufacturer.  All
sample included had a call rate of >97% with an average of
99.67±0.37%.  Single-nucleotide  polymorphisms  (SNPs)
were excluded if they showed either: (i) a total call rate of
<95% in the cases and controls combined; (ii) a minor allele
frequency of <5% and a total call rate of <99% in the cases
and  controls  combined;  (iii)  significant  distortion  from
Hardy–Weinberg equilibrium in the controls (p value <10−7).
In sum, 517,401 SNPs (92.36%) passed the quality control
filter  with  an  average  call  rate  of  99.91%.  Genotyping
validation was performed using the Sequenom iPLEX assay
(SEQUENOM MassARRAY system; Sequenom, San Diego,
CA) [14-16]. Visualized and analyzed data could be generated
by the Illumina's platforms.
Statistical analysis: Association analysis was performed
to  compare  allele  frequency  and  genotype  distribution
between cases and controls using five single-point methods:
genotype, allele-type, and Cochran-Armitage trend test along
with  tests  considering  dominant  and  recessive  inheritance
modes.  Empirical  p-values  were  also  obtained  with  107
simulations. SNPs with p-values between 10−7 and 10−5, a cut-
off  for  the  multiple-comparison  adjusted  by  Bonferroni
correction, were considered to be significantly associated with
the  traits.  All  five  SNPs  were  analyzed  with  the
HAPLOVIEW program, v4.1.
RESULTS
A total of 968 unrelated individuals with T2D, over 20 years
of  age,  were  recruited  from  China  Medical  University
Hospital (CMUH), Taiwan. The T2D patients with a LOCS
cataract score equal to or less than 3 and with a BCVA (best
corrected visual acuity) of 0.18 logMAR (6/9) or better were
included in the control group. The T2D patients with a cataract
score of 10 or more in LOCS cataract evaluation system and
with a BCVA of 0.48 logMAR (6/18) or worse were included
in the cataract group. The patients that met the criteria were
109 and 649, respectively. Average intraocular pressure (IOP)
was  15.36  mmHg  and  15.86  mmHg,  respectively.  The
characteristics of the T2D patients with cataracts and without
cataracts can be seen in Table 3. The physical conditions of
the T2D patients are expressed in Table 4. We conducted a
genome-wide association study (GWAS) to simultaneously
identify genetic variants for T2D patients with cataracts in
Han-Chinese residing in Taiwan. We started with 517,401
SNPs that passed quality control filters using the Illumina
Hap550duov3 chip. In the study, we found three SNPs with
significant evidence (p<10−7) for association with diabetic
cataracts, locus at chromosome 3p14.1- 3p14.2 (rs11129182,
rs17047573,  and  rs17047586)  (p  value=3.52×10−7,  8.
35×10−8, and 7.65×10−8, respectively; Table 4). In the three
SNPs,  the  CT  genotype  of  rs11129182,  GG  genotype  of
rs17047573,  and  the  GG  genotype  of  rs17047586  were
significantly different in the T2D with cataracts and T2D
without  cataracts  groups  (OR=3.03,  7.47,  and  7.51,
respectively; 95% confidence interval (CI): 1.97–4.65, 3.36–
16.6, and 3.38–16.7, respectively; Table 5). We found that
there were four haplotypes composed by the polymorphisms
(Table 6). We defined haplotype 1 (Ht 1) to haplotype 4 (Ht
4) as the alternative alleles of the DM and cataract related
3p14.1- 3p14.2 polymorphisms (Table 5). Ht1 (G/C) and Ht2
(A/T) were composed by rs9876471 and rs264667 and Ht3
TABLE 2. LENS OPACITIES CLASSIFICATION SYSTEM DEFINES THE EXTENT OF OPACIFICATION OF LENS CORTEX OPACIFICATION AND POSTERIOR
SUBCAPSULE OF LENS.
Cortical standard Description
C0 Clear lens devoid of aggregated dots, flecks,
Ctr Minimal degree of cortical opacification and/or
CI More extensive opacification with small
CII Cortical spoking that obscures more than 2 full
CIII Opacification that obscures about 50% of the
CIV Advanced opacification filling about 90% of the
Posterior subcapsule standard Description
P0 Clear posterior capsule
PI Cataract filling about 3% of the area of the posterior capsule
PII About 30% opacification of the area of the posterior capsule
PIII About 50% opacification of the area of the posterior capsule
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1208(T/A) and Ht4 (G/G) were composed by rs17047573 and
rs17047586. The distribution of the Ht3 and Ht4 between the
DM  and  cataract  group  and  the  control  group  differed
significantly between the two groups (p=0.0004). The odds
ratio (OR) of Ht4 was 1.89 and the 95% confidence interval
(CI) was 1.36–2.65.
DISCUSSION
The cut down of cataract level were LOCS 3 and 10 and the
BCVA were 0.48 and 0.18 logMAR in this study. The patients
who matched both the criteria of cataract level and visual
acuity were included in the control and study groups. Because
the  patients  with  LOCS  cataract  scores  of  less  than  3  or
between LOCS 3–10 all had some form of cataract, the BCVA
of the patients was also the including criteria. In addition, the
progression of their cataracts might occur soon, the including
criteria of cataracts and the control group was not a cut point.
The patient with LOCS cataract scores of 3–10 were excluded
from this study. In this study, we selected the patients with
cataracts and poor BCVA as the study group and the patients
with contrary criteria as the control group. The patient with
senile cataracts could not be completely excluded; this was
the limitation of our study. Nevertheless, the severity of the
cataracts was the major criteria of the two groups. That is, the
patients  with  the  similar  physical  conditions  and  various
severity of cataract were compared. A large amount of efforts
has been devoted to finding common T2D genes, including
genome-wide  linkage,  candidate-gene  and  genome-wide
association studies [17]. Whole-genome linkage scans have
identified chromosomal regions linked to T2D [18]. There are
now at least 20 loci containing genes that increase the risk of
T2D,  including  potassium  channels  (KCNJ11  [potassium
inwardly-rectifying channel, subfamily J, member 11] and
KCNQ1  [potassium  voltage-gated  channel,  KQT-like
subfamily, member 1]) [19], cell cycle regulators (CDKAL1
[regulatory  subunit  associated  protein  1-like  1],
CDKN2A-2B [cyclin-dependent kinase inhibitor 2A-2B], and
CDC123-CAMK1D  [cell  division  cycle  123  homolog-
calcium/calmodulin-dependent  protein  kinase  ID])  [20],
nuclear hormone receptor (PPARG [peroxisome proliferator-
activated  receptor  gamma])  [21],  melatonin  receptor
(MTNR1B [melatonin receptor 1B]) [22], transcription factors
(TCF7L2  [transcription  factor  7-like  2],  TCF2  or  HNF1B
[hepatocyte nuclear factor 1 beta], HHEX [hematopoietically
expressed  homeobox],  and  JAZF1  [JAZF  zinc  finger  1])
[23], translational regulator (IGF2BP2 [insulin-like growth
factor  2  mRNA  binding  protein  2])  [24],  zinc  transporter
(SLC30A8 [solute carrier family 30 zinc transporter member
8]) [25], apoptosis components (THADA [thyroid adenoma
associated])  [26],  metalloprotease  (ADAMTS9  [ADAM
metallopeptidase with thrombospondin type 1 motif, 9]) [27],
calcium homeostasis component (WFS1 [Wolfram syndrome
1  homolog])  [28],  fat  mass  and  obesity-associated  gene
(FTO  [fat  mass  and  obesity  associated])  [29],  pancreas
organogenesis  (NOTCH2  [Notch  homolog  2])  [30],  and
surface glycoprotein (TSPAN8 [tetraspanin-8]) [31]. Variants
in these genes are almost exclusively identified in population
of European descent, and individually confer a modest risk
(odds ratio=1.1–1.25) of developing T2D [31]. The ethnic
differences in the genetic component are remarkable and the
TABLE 3. CHARACTERISTICS OF T2D PATIENTS WITH AND WITHOUT CATARACT.
Characteristics T2D with cataract T2D without cataract
Age (y/o) 62±2.35 (20–70) 63±1.75 (20–70)
F/M 57/52 332/317
BCVA 1.53±0.13 (0.48–2) 0.04±0.03 (0–0.18)
IOP (mmHg) 12.5±0.3 (7–21) 13.2±0.2 (7–21)
In the table, the term “F/M” indicates female/male and “BCVA” indicates best corrected visual acuity.
TABLE 4. THE PHYSICAL CONDITION OF THE T2D PATIENTS.
Variable Mean C/N Std Dev C/N Min C/N Max C/N
BUN 17.42/17.32 8.17/8.15 5.80/5.70 87.10/82.20
Creatinine 0.91/0.90 0.58/0.62 0.23/0.29 13.80/12.95
total-cholesterol 189.02/187.10 41.23/41.08 66.00/68.20 560.00/550.20
triglyceride 163.82/163.84 125.63/126.58 58.90/21.00 1380.00/1327.60
HDL-C 48.75/48.67 13.75/13.82 8.25/8.00 111.00/108.50
LDL-C 118.52/117.64 35.77/34.68 3.75/3.20 338.20/335.20
HbA1C 7.94/7.92 1.45/1.49 4.20/4.50 16.20/15.90
In the table, “HDL-C” indicates high-density lipoprotein cholesterol and “LDL-C” indicates low-density lipoprotein cholesterol.
In the column headers, “C/N” indicates T2D patient with cataract/T2D patient without cataract.
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1210establishment of the genetic predisposition of our population
is also important. The three SNPs with significant differences
were found in cataract and T2D patients in this study, and were
located at chromosome 3p14.1- 3p14.2. SNP rs11129182 with
significant difference (p=3.52×10−7) in the patient with T2D
and cataract simultaneously, and ‘CT’ genotype was a risk
marker (OR=3.03, 95% CI: 1.97–4.65) of the patients of T2D
suffered cataract simultaneously. SNP rs11129182, located on
chromosome 3p14.2, the gene and the genes locate in this
region were with the function of regulate potassium voltage-
gated channel, thyroid hormone receptors, and retinoic acid
receptors. The high correlative rate of DM and cataracts in
SNP rs11129182 was reasonable, but the exact effect of the
SNP  is  worth  elucidation.  SNPs  rs17047573  and
rs17047586 (p value=8.35×10−8 and 7.65×10−8, individually;
Table 3) expressed significant difference in the T2D patients
with  cataract.  ‘GG’  genotype  of  rs17047573  and  ‘GG’
genotype of rs17047586 were risk factors for T2D patients
suffering from cataracts (7.47 and 7.51, individually; 95%
confidence index (CI): 1.97–4.65, 3.36–16.6, and 3.38–16.7,
individually). SNPs rs17047573 and rs17047586 are located
at chromosome 3p14.1. The functions of the genes locates at
chromosome  3p14.1  include  voltage-dependent  anion-
selective channel protein, long myosin light chain kinase,
adenylyl  cyclase-associated  protein,  and  retinoic  acid
receptor.
T2D and potassium voltage-gated channel: In previous
research by Unoki et al. [8], from 268,068 SNPs selected from
the JSNP21 or HapMap database [32], potassium channels
(KCNJ11 and KCNQ1) were discovered to associate with the
T2D in populations of both East Asian and European descent.
KCNQ1 is located on chromosome 11p15.5 and is expressed
in the pancreatic islets [33]. KCNQ1 encodes the pore-forming
subunit of the potassium channel. This evidence suggests that
potassium channels might contribute to the pathogenesis of
T2D [8,9].
T2D and thyroid hormone receptor: Thyroid hormone
analogs might be used to prevent or combat atherosclerosis,
obesity and even T2D [34,35]. Current knowledge of thyroid
hormone signaling suggests that thyroid hormone mimetics
could worsen or improve different aspects of T2D. Thyroid
hormone  produces  changes  in  hormone  levels  and  gene
profiles that resemble fasting states, in which insulin signaling
should  be  reduced,  and  thyroid  hormone  stimulates  liver
gluconeogenesis, which increases blood glucose levels [36].
Conversely,  thyroid  hormone  reduces  body  fat,  reverses
hepatic  steatosis  and  increases  mitochondrial  activity  [37,
38], effects that could be protective against T2D.
T2D and retinoic acid receptor: Neuropathy is the most
common complication of DM; it occurs in 60% of patients and
affects their quality of life [39,40]. Diabetic neuropathy is
characterized by a progressive loss of nervous myelinic and
amyelinic fibers. Retinoic acid had the significant effect of
increasing neural growth factors in nerves when the other
groups were compared to animals with DM [41]. Retinoic acid
also regressed the ultrastructural changes induced by diabetes
that showed increased neural regeneration [41]. RA can revert
functional  and  ultrastructural  changes  and  induce  neural
regeneration after the establishment of diabetic neuropathy.
Retinoic  acid  is  an  essential  molecule  for  cellular
differentiation  and  an  important  morphogen  in  somatic
development by binding to nuclear receptors and transcription
complexes [41]. Other studies also indicated that retinoic acid
might  have  renoprotective  effects  in  the  early  stages  of
diabetic  nephropathy  through  anti-inflammatory  activity
[42]. Moreover, one interesting study indicated that the serum
levels  of  retinoic  acids  in  diabetic  patients  correlated
positively with the hemoglobin A1c (HbA1c) values. This
evidence all supports the correlation between retinoic acid and
DM [43].
T2D  and  myosin  light  chain  kinase:  Diabetes-related
cardiovascular disease remains the leading cause of death in
patients  with  T2D  [44].  Hypertension  is  common  among
diabetics  and  has  the  same  pathogenetic  mechanisms  as
insulin resistance, in which the activated renin–angiotensin
system contributes to the increased high blood pressure and
hyperglycemia. Hyperglycemia is one of the triggering factors
for  vascular  dysfunction  and  clotting  abnormalities,  and
TABLE 6. ODDS RATIO AND 95% CI FOR THE ASSOCIATION BETWEEN HAPLOTYPES IN 3P14.1- 3P14.2 AND MYOPIA.
Haplotype        
rs9876471                 rs264668 Cases Control OR (95% CI) p-value/Cp-value
G C Ht1 88.1% 91.9% 1.00 (Ref) 0.420/0.820
A T Ht2 9.6% 7.9% 1.27 (0.77–2.08)  
rs17047573              rs17047586          
T A Ht3 73.4% 83.7% 1.00 (Ref) 0.0002/0.0004
G G Ht4 26.6% 16.0% 1.89 (1.36–2.65)  
In the table, “CI” indicates confidence interval. The χ2 test or Fisher's exact test was performed to obtain the p-value. The
percentages of myopia and control with ht1 were compared with the percentages of myopia and control without ht1. Statistical
significance was considered as p-value <0.05. The Cp-value is the p-value corrected by Bonferroni correction.
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Furthermore,  angiotensin-converting  enzyme  inhibitors
might offer additional cardioprotection to diabetics beyond
that  provided  by  blood  pressure  reduction.  The
phosphorylation of myosin light chain in cardiac muscles by
calmodulin-dependent kinase and has the modulatory role in
the  activation  of  myofibrillar  adenosine  triphosphatase
(ATPase) and the process of force generation [44-47]. The
myosin light chain is an important molecule in the diabetes-
related cardiovascular disease [44-47].
T2D  and  adenylyl  cyclase-associated  protein:  Gia
proteins  are  associated  with  functions  in  the  aorta  of  the
streptozotocin-induced diabetic rats [48]. A previous study by
Hashim et al. [48] indicated that decreased levels and activity
of Gi proteins and adenylyl cyclase signaling induced by
hyperglycemia  may  be  one  of  the  important  mechanisms
contributing to the cardiovascular complications associated
with diabetes [48,49].
Cataract  and  the  related  proteins:  The  voltage-gated
channel influences the intracellular iron concentrations that
are closely related to denature of crystalline and influenced
the cataract formation [50,51]. Thyroid hormones can confer
a protective effect against oxidative damage, which is one of
the main causes of damages to cells in the eye's lens and is
related to the formation of cataracts [52-54]. Retinoic acid
(RA)-mediated inhibition of deregulated calpains has effects
on  the  development  of  cataracts  [55].  RA  inhibits  Ca2+
elevation  and  subsequent  overactivation  of  calpains,
suggesting  the  potential  feasibility  of  calpain-targeting
therapies mediated by RA for cataracts [39-41]. MLC (myosin
light chain) phosphorylation is noted to play an important role
in maintaining lens function by regulating Rho kinase [55,
56]. Adenylyl cyclase-associated protein was identified as a
most efficient substrate of matrix metalloproteinases (MMP)
[57]. Lens crystallins illustrates that intracellular structural
proteins are MMP substrates. Adenylyl cyclase-associated
protein can induce the rapid turnover rate of MMP-9 [57].
Lens opacity may be related to adenylyl cyclase-associated
protein  [57].  These  protein  all  are  related  to  the
cataractogenesis  and  the  pathogenesis  of  T2D.  In  the
haplotype study, Ht4 was significantly higher in the cases
group and with an odd ratio: 1.89 and 95% CI:1.36–2.65. This
meant that Ht4 was a risk factor for susceptibility to cataracts
and  DM.  This  evidence  makes  us  realize  the  correlation
between rs11129182, rs17047573, and rs17047586 with T2D
and cataract and helps us in predicting and designing new
diagnoses  and  treatment  methods  for  T2D  patients  with
cataracts.
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